NEW YORK, July 20, 2015 /PRNewswire/ -- How will breast cancer be treated in the years ahead – and what targeted therapies represent the greatest potential in terms of transforming disease therapy?
KOL Insight: Breast Cancer provides a comprehensive qualitative review of marketed and pipeline therapies in the breast cancer market with an emphasis on current and future treatment pathways. Interviews with 12 Key Opinion Leaders from the US and Europe add future-facing perspective and insights to the data.
This report includes key insights on the characterisation of optimal sequencing for HER2-positive breast cancer and how this might change, as well as the potential for new therapies for HER2-negative/HR-positive breast cancer and triple-negative breast cancer which may alter the treatment paradigm. The introduction of new CDK inhibitors, as well as the potential approval of PARP inhibitors in the future, are set to change the way the disease is treated.
Key Benefits
Better understand how your product is perceived, or likely to be perceived, by the marketplace
Learn about the strengths and weaknesses of your competitors
Understand different approaches to positioning that will put your product in the most favorable light possible
Understand where the opportunities and threats are in the marketplace
Gain insights required to better direct your sales and/or marketing teams toward success
Answers to Critical Questions
Which drug is the treatment of choice for each patient segment, and what product attributes shape preference?
Which clinical trials have the greatest potential to impact prescribing trends?
How will the use of each product evolve in the future in terms of line of therapy and preference?
How will the treatment landscape evolve in the future for each patient segment and line of therapy?
What are the experts' greatest concerns about new and future therapies?
Pipeline Therapies Covered
AbbVie veliparib (ABT 888)
AstraZeneca olaparib (Lynparza)
BioMarin Pharmaceutical talazoparib (BMN 673)
Boehringer Ingelheim Gilotrif (afatinib)
Eli Lilly abemaciclib (LY 2835219)
Galena Biopharma NeuVax (nelipepimut-S)
Merck & Co./Tesaro niraparib (MK 4827)
Novartis/Astex ribociclib (LEE 011)
Novartis buparlisib (BKM 120)
Puma Biotechnology neratinib
Roche/Genentech taselisib (GDC 0032)
Syndax Pharmaceuticals entinostat (SNDX 275)
Marketed Drugs Covered
Genentech/Roche/Chugai Herceptin (trastuzumab)
Genentech/Roche/Chugai Kadcyla (ado-trastuzumab emtansine)
Genentech/Roche/Chugai Perjeta (pertuzumab)
GlaxoSmithKline/Nippon Kayaku Tykerb (lapatanib)
Novartis Afinitor (everolimus)
Pfizer Ibrance (palbociclib)
Report Features
Comprehensive commercial and clinical profiles of each targeted therapy currently in market
Summaries and analyses of all significant clinical trials now underway
Overviews of current treatment algorithms based on patient segment, line of therapy, and patient characteristics
The opinions and insights of a dozen KOLs, split equally between the US and Europe
Summaries and analyses of current and future treatment pathways
Key Opinion Leaders
North America
Dr. Adam M. Brufsky, MD, PhD, Professor of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA
Dr. Richard Finn, MD, Assistant Professor of Medicine, Geffen School of Medicine at UCLA, Department of Medicine, Division of Hematology/Oncology, Los Angeles, CA
Dr. Reshma Mahtani, DO, Assistant Professor of Clinical Medicine, Division of Hematology/Oncology, Miller School of Medicine, University of Miami, Miami, FL
Dr. Erica L. Mayer, MD MPH, Senior Physician, Susan F. Smith Center for Women's Cancers at the Dana-Farber Cancer Institute, Boston, MA; Assistant Professor in Medicine, Harvard Medical School, Boston, MA
Dr. Joyce O'Shaughnessy, MD, Co-Chair of Breast Cancer Research, Baylor-Charles A. Sammons Cancer Center, Dallas, TX
Dr. Charles Vogel, MD, Professor of Clinical Medicine, Division of Hematology/Oncology, Miller School of Medicine, University of Miami, Miami, FL
Europe
Dr. Thomas Bachelot, MD, Head, Breast Cancer Unit and the Clinical Trial Unit, Centre Leon Berard, Lyon, France
Dr. Adrian L. Harris, MD, DPhil, Professor of Medical Oncology, University of Oxford; Director, Cancer Research UK Medical Oncology Unit
Dr. Chris Twelves, Professor of Clinical Cancer Pharmacology and Oncology and Head of Section of Oncology and Clinical Research, Leeds Cancer Research UK Centre, Leeds, UK
Dr. Etienne GC Brain, MD PhD, Medical Oncologist, Hôpital René Huguenin, Saint-Cloud, France
Dr. Véronique Diéras, MD, Head, Department of Clinical Research and Chief of the Clinical Investigational Unit, Institut Curie, Paris, France and Saint Cloud, France
Dr. Rafael Trujillo Vilchez, Medical Oncologist, Xanit International Hospital, Malaga, Spain
Update Bulletins Offer Ongoing Benefits
The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, May 2015.
You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.
Read the full report: http://www.reportlinker.com/p03090967-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article